Spondylitis ankylopoetica (Bechterew-kór): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• IL-17 3
• TNF 2
• JAK 1
• IL-23 1
• NLRP3 0
• STAT3 0
• TLR4 0
• COX-2 0
• IL-6 0
• MAPK 0
• NRF2 0
• PD-1 0
• AKT 0
• AXL 0
• BDNF 0
• CD40 0
• CGRP 0
• CXCR4 0
• ERK 0
• FAK 0
• G6PD 0
• HIF-1 0
• IL-1 0
• IL-15 0
• MEK 0
• NF1 0
• PD-L1 0
• PI3K 0
• PIK3CA 0
• PPAR 0
• PTEN 0
• RANKL 0
• VEGF 0

712 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R56

  Identifying pre-osteoarthritis endotypes and mechanisms

  Hebrew Rehabilitation Center for Aged· Boston, Egyesült Államok· 604 389 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIAMS · R01

  Defining Early Events in the Pathogenesis of Axial Spondyloarthritis

  Washington University· Saint Louis, Egyesült Államok· 546 057 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIAID · R03

  Understanding the Development of Human Type 17 CD8 T Cells

  Washington University· Saint Louis, Egyesült Államok· 77 750 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIAMS · K08

  Use of Antenatal Disease Modifying Antirheumatic Drugs and Maternal-child Health Among Women with Chronic Inflammatory Arthritis

  Yale University· New Haven, Egyesült Államok· 160 024 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIAMS · K23

  Tailored Exercise Interventions for Patients with Axial Spondyloarthritis: Targeting Sex-Based Challenges to Improve Clinical Outcomes

  University of Washington· Seattle, Egyesült Államok· 169 668 USD awarded in fiscal year 2026· until 2031. ápr.

• European Commission (Horizon Europe) · HORIZON-IA

  CANVAS: STREET FURNITURE AS A CANVAS - BEAUTY, INCLUSION AND SUSTAINABILITY IN PUBLIC SPACE

  Ait Austrian Institute of Technology Gmbh· Wien, Ausztria· EU contribution 5 110 818 EUR· until 2030. aug.· 10 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE BLINDED RANDOMIZED CONTROLLED TRIAL (PRoRota)

  Universitetet I Bergen· Bergen, Norvégia· EU contribution 5 299 999 EUR· until 2030. ápr.· 4 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  NEXT-GENERATION SCALABLE AEM ELECTROLYZERS AS SUSTAINABLE HYDROGEN PRODUCTION SYSTEM (NEREUS)

  Antares Electrolysis S.r.l.· Genova, Olaszország· EU contribution 3 999 786 EUR· until 2029. febr.· 7 countries

• European Commission (Horizon Europe) · HORIZON-CSA

  OPERATING OPEN RESEARCH EUROPE AS A NON-PROFIT OPEN ACCESS SCIENTIFIC PUBLISHING SERVICE FOR THE PUBLIC GOOD (ORE 2.0)

  Organisation Europeenne Pour la Recherche Nucleaire· Geneve 23, Svájc· EU contribution 9 996 090 EUR· until 2030. dec.

• European Commission (Horizon Europe) · HORIZON-RIA

  CARBON-NEUTRAL PRODUCTION AND DIRECT FUEL-CELL DEPLOYMENT OF ISOPROPANOL AS ENERGY CARRIER (IsoPROPEL)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 3 995 636 EUR· until 2029. ápr.· 8 countries

10 of 44 running projects, newest first. Listed amounts together: 10,9 M USD + 89,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Hematological Parameters in Axial Spondyloarthritis

  NCT05450133· Bozyaka Training and Research Hospital· Frissítve: 2025. máj. 1.

  “primary researcher is not avaible to recruit participants”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

  NCT06715254· Novartis Pharmaceuticals· Frissítve: 2024. dec. 4.

  “Due to the limited availability of eligible patients who met the study's criteria, as well as there has not been a case of tuberculosis, the study was terminated early.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Terbinafine Treatment of Axial Spondyloarthropathy

  NCT05119712· Oregon Health and Science University· Frissítve: 2023. aug. 28.

  “Study stopped due to poor recruitment.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy

  NCT04483687· Gilead Sciences· Frissítve: 2021. jan. 11.

  “Development program terminated”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy

  NCT04483700· Gilead Sciences· Frissítve: 2021. jan. 11.

  “Development program terminated”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

  NCT07133633· Merck Sharp & Dohme LLC· Forrás

• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

  NCT04638647· Novartis Pharma AG· Forrás

• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

  NCT04436640· UCB Biopharma SRL· Forrás

• Inspiratory Muscle Training in Axial Spondyloarthritis

  NCT07914439· Bursa Yuksek Ihtisas Training and Research Hospital· Forrás

• An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

  NCT06668181· UCB Biopharma SRL· Forrás

• Nurse-Led Exercise Program for Older Adults With Ankylosing Spondylitis

  NCT07891507· Mansoura University· Forrás

• A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

  NCT05622708· Novartis Pharmaceuticals· Forrás

• Taekwondo for Axial Spondyloarthritis

  NCT06823726· Wonju Severance Christian Hospital· Forrás

• Optimizing treatment strategy in axial spondyloarthritis by molecular imaging with Technetium-labeled certolizumab pegol.

  2023-505694-32-00· Universitair Ziekenhuis Gent· Forrás

• A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

  NCT04527380· Eli Lilly and Company· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 7
• Mendelian Randomization Analysis 20
• Gene Expression Profiling 12
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 9
• Metabolomics 5
• Flow Cytometry 3
• Magnetic Resonance Imaging 72
• Machine Learning 10
• Deep Learning 8
• Cohort Studies 24
• Genome-Wide Association Study 24

• EXTL3 dysfunction identified as a driver of aberrant bone development in severe familial ankylosing spondylitis.

  Ann Rheum Dis, 2026. aug.

• [Clinical phenotype and genetic analysis of a patient with Progressive pseudorheumatoid dysplasia due to compound heterozygous variants of CCN6 gene and a literature review].

  Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2025. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.